Allogene Therapeutics, Inc.

NASDAQ:ALLO

Biotechnology

Healthcare
$0.70 +1.02%

+$0.02 today

Market cap
$241.11M
Beta
0.46
P/E (TTM)
-2.7
EPS (TTM)
-$0.72
52W Low $0.98High $4.46

Volume 10.55M

Average 10.19M

ALLO Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Allogene Therapeutics, Inc.NASDAQ: ALLO

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares growth accelerates

Q1 FY2026 weighted avg shares of 240.29M shares rose 11.6% year over year, ahead of the +9.3% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 8.9% from the prior quarter. Over 3 fiscal years it compounded at +15.5% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +11.6% holds above the trailing-twelve-month pace of +9.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
240.29M+8.9% QoQ
Last fiscal yearDec 2025
220.62M+13.2% YoY
LTMMar 2026
225.47M+9.3% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+11.6%——
1 year+13.2%——
3-year CAGR+15.5%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
220.62M USD
Year-over-year change
+13.2%
4-year CAGR
+12.9%

Weighted Avg Shares vs competitors

How ALLO compares with its peers on the latest reported figures

  • ALLO's LTM Mar 2026 weighted avg shares of 225.47M shares is the 2nd highest of the 9 companies compared; the peer median is 90.32M shares.
  • Its year-over-year change of +9.3% is the 4th highest of 9, against a peer median of +3.9%.
  • Over three fiscal years its annual growth of +15.5% compares with a peer median of +26.2%.
ALLO Competitors Peer median
Weighted Avg Shares for ALLO and competitors
Company Period LTM YoY 3-year CAGR
AUTLAutolus Therapeutics plcLTM Mar 2026266.14M +0.0%+41.0%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026225.47M +9.3%+15.5%
FATEFate Therapeutics, Inc.LTM Mar 2026119.09M +1.0%+7.1%
CLLSCellectis S.A.LTM Mar 2026100.38M +2.9%+30.1%
CRBUCaribou Biosciences, Inc.LTM Mar 202694.18M +3.6%+15.4%
IPSCCentury Therapeutics, Inc.LTM Mar 202686.45M +4.3%+14.4%
CELUCelularity Inc.LTM Dec 202524.87M +13.6%+22.3%
ATRAAtara Biotherapeutics, Inc.LTM Mar 202613.1M +49.4%+45.4%
DTILPrecision BioSciences, Inc.LTM Mar 202612.13M +61.6%+63.6%
Peer median (excluding ALLO) 90.32M+3.9%+26.2%

Competitors are the stored peer set for ALLO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue114.09M156K95K22K0
Cost of Revenue014.3M0012.36M
Gross Profit114.09M(14.14M)95K22K(12.36M)
Gross Margin100.0%-9063.5%100.0%100.0%—
Research & Development220.18M256.39M242.91M192.3M150.15M
Selling, General & Admin74.11M79.31M71.67M65.21M56.78M
Operating Expenses294.28M321.4M327.83M273.22M194.57M
Depreciation & Amortization10.45M14.3M14.2M13.64M12.36M
EBITDA(171.6M)(326.12M)(313.07M)(243.33M)(177.45M)
EBITDA Margin-150.4%-209050.6%-329543.2%-1106031.8%—
Operating Income(180.19M)(335.54M)(327.74M)(273.2M)(206.93M)
Operating Margin-157.9%-215087.2%-344986.3%-1241813.6%—
Interest Income1.71M4.57M18.31M20.15M19.29M
Interest Expense000181K1.08M
Other Income / Expenses(1.86M)(4.88M)472K16.05M16.05M
Income Before Tax(182.05M)(340.41M)(327.27M)(257.15M)(190.89M)
Pre-Tax Margin-159.6%-218214.1%-344489.5%-1168850.0%—
Income Tax Expense000443K0
Net Income(182.05M)(340.41M)(327.27M)(257.59M)(190.89M)
Net Margin-159.6%-218214.1%-344489.5%-1170863.6%—
EPS (Basic)(1.34)(2.38)(2.09)(1.32)(0.87)
EPS (Diluted)(1.34)(2.38)(2.09)(1.32)(0.87)
Weighted Avg Shares135.82M143.15M156.93M194.81M220.62M
Weighted Avg Shares (Diluted)135.82M143.15M156.93M194.81M220.62M

Allogene Therapeutics, Inc.

NASDAQ:ALLO

Intrinsic Alpha fair value

Locked

Current Price

$0.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.